Recombinant-HER2 protein vaccine (20, 100, and 500 μg) in conjugation with an immunostimulant (AS15) also exhibited a satisfactory safety profile in HER2 + breast cancer patients in a phase I trial (NCT00058526). This evidence concerns the gene ERBB2 and breast cancer.